COCRYSTAL PHARMA NEW O.N. (8CC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has a cash flow conversion efficiency ratio of -0.274x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.74 Million ≈ $-2.03 Million USD) by net assets (€6.33 Million ≈ $7.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 8CC market cap overview for the company's overall valuation and market capitalisation.
COCRYSTAL PHARMA NEW O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
COCRYSTAL PHARMA NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their cash flow conversion efficiency. See debt repayment capacity of COCRYSTAL PHARMA NEW O.N. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pharma Equity Group A/S Cl A
CO:PEG
|
-0.261x |
|
Youngsin Metal Industrial Co. Ltd
KQ:007530
|
0.067x |
|
East Africa Metals Inc.
V:EAM
|
-0.113x |
|
SPAR Group Inc
NASDAQ:SGRP
|
-0.245x |
|
PeterLabs Holdings Bhd
KLSE:0171
|
0.107x |
|
Niocan Inc
V:NIO
|
-0.039x |
|
Swvl Holdings Corp
NASDAQ:SWVL
|
-0.177x |
|
Initiator Pharma A/S
ST:INIT
|
-0.144x |
Annual Cash Flow Conversion Efficiency for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. View COCRYSTAL PHARMA NEW O.N. (8CC) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.33 Million ≈ $7.40 Million |
€-8.19 Million ≈ $-9.58 Million |
-1.294x | +25.25% |
| 2024-12-31 | €9.52 Million ≈ $11.13 Million |
€-16.48 Million ≈ $-19.27 Million |
-1.731x | -211.42% |
| 2023-12-31 | €26.38 Million ≈ $30.85 Million |
€-14.67 Million ≈ $-17.15 Million |
-0.556x | -2.61% |
| 2022-12-31 | €39.57 Million ≈ $46.26 Million |
€-21.43 Million ≈ $-25.06 Million |
-0.542x | -230.30% |
| 2021-12-31 | €77.55 Million ≈ $90.66 Million |
€-12.72 Million ≈ $-14.87 Million |
-0.164x | -- |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more